Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Altimmune Inc is a biotechnology business based in the US. Altimmune shares (ALT) are listed on the NASDAQ and all prices are listed in US Dollars. Altimmune employs 43 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Active traders
Our top pick for
Beginners
Our top pick for
Building a portfolio
| Latest market close | $7.84 |
|---|---|
| 52-week range | $7.35 - $24.61 |
| 50-day moving average | $9.64 |
| 200-day moving average | $11.95 |
| Wall St. target price | $31.67 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-2.11 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $7.84 from 2022-01-14
| 1 week (2022-01-10) | -4.04% |
|---|---|
| 1 month (2021-12-17) | -16.24% |
| 3 months (2021-10-15) | -34.72% |
| 6 months (2021-07-17) | -16.06% |
| 1 year (2021-01-15) | -39.37% |
|---|---|
| 2 years (2020-01-17) | 326.09% |
| 3 years (2019-01-17) | 152.90% |
| 5 years (2017-01-17) | 33.5 |
| Revenue TTM | $3.4 million |
|---|---|
| Gross profit TTM | $-25,324,291 |
| Return on assets TTM | -21.31% |
| Return on equity TTM | -40.99% |
| Profit margin | 0% |
| Book value | $5.28 |
| Market capitalisation | $311.6 million |
TTM: trailing 12 months
We're not expecting Altimmune to pay a dividend over the next 12 months.
Altimmune's shares were split on a 1:30 basis on 13 September 2018. So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Altimmune shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Altimmune shares which in turn could have impacted Altimmune's share price.
Over the last 12 months, Altimmune's shares have ranged in value from as little as $7.35 up to $24.61. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Altimmune's is 1.3573. This would suggest that Altimmune's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Altimmune, Inc. , a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company develops T-COVID, an intranasal immune modulating therapeutic candidate, which is in Phase 1/2 clinical trials to prevent clinical worsening in patients with early COVID-19; NasoShield, an anthrax vaccine product candidate that is in a Phase 1b trial; and NasoVAX, a recombinant intranasal vaccine product candidate for seasonal and pandemic use. It also focuses on developing pemvidutide, a next generation peptide therapeutics for non-alcoholic steatohepatitis; and HepTcell, an immunotherapeutic product candidate that is in Phase 2 studies for patients chronically infected with the hepatitis B virus. The company is headquartered in Gaithersburg, Maryland. .
Donut earns up to 10% APY, but you must have an iOS device.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.
Everything we know about the VinFast IPO, plus information on how to buy in.
Creating a golf club is a thus-far unique application of NFTs, and another step forward for the decentralized economy.
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.
Everything we know about the Specialty Building Products IPO, plus information on how to buy in.
Everything we know about the HeartCore Enterprises IPO, plus information on how to buy in.
